CClinicalTrials.gg
RecruitingNCT05949268Updated May 1, 2026

Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel

An observational study in GastroIntestinal Bleeding, sponsored by University Hospital Freiburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University Hospital Freiburg · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,300
Ages
18 Years and older
Sex
All
01

Study summary

Small bowel capsule endoscopy is the main diagnostic standard for small bowel bleeding. This study investigates the detection rate of small bowel bleeding in capsule endoscopy and further endoscopic treatment in a prospective and retrospective cohort.

Read the detailed description

Small bowel capsule endoscopy is considered the diagnostic gold standard in the diagnosis of diseases of the small bowel. Most indications for capsule endoscopy are overt small bowel bleedings - defined as gastrointestinal bleeding after negative gastroscopy and colonoscopy - or occult iron deficiency anemia. Timing of small bowel capsule endoscopy seems to be decisive for the diagnosis of small bowel bleeding: corresponding to the actual guidelines the detection of small bowel bleeding can be up to > 70% if the intervention is performed within 2 days. Treatment of small bowel bleedings can be performed with small bowel enteroscopy such as balloon or motorized spiral enteroscopy. Against this background this study investigates the rate of small bowel bleeding diagnosed in capsule endoscopy. The aim of the study is to report tumorous, vascular and inflammatory findings as well as complications and cecal accessibility. One focus of the study is the time between small bowel bleeding and small bowel capsule endoscopy and small bowel enteroscopy, respectively. Endoscopic therapies and further bleeding episodes are recorded. In order to determine the improved clinical outcome after the introduction of the shortened timing for recommendation published in 2022, a retrospective cohort should be included in addition to a prospective cohort.

02

Conditions studied

  • GastroIntestinal Bleeding

Keywords

  • Small bowel capsule endoscopy
  • gastrointestinal bleeding
  • anticaogulation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who present with gastrointestinal bleeding undetected in gastroscopy or colonoscopy will be included in this cohort study. In these patients bleeding in the small bowel is suspected and they are allocated to a diagnostic assessment with small bowel capsule endoscopy.

Inclusion criteria

  • suspicion of gastrointestinal bleeding in the small bowel undetected by gastroscopy and colonoscopy
  • informed consent

Exclusion criteria

Exclusion Criteria:

  • contraindications for small bowel capsule endoscopy (e.g. stenosis)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with gastrointestinal bleeding undetected in gastroscopy and colonoscopy

    Gastrointestinal bleeding in the small bowel.

    Device: Small bowel capsule endoscopy

Interventions

  • DeviceSmall bowel capsule endoscopy

    Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.

05

What researchers measure

Primary outcomes

  1. Prevalence of small bowel bleeding detected during small bowel capsule endoscopy

    Detection of bleeding during small bowel capsule endoscopy

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Prevalence of vascular lesions as source of bleeding

    Detection of vascular lesions angiodysplasia) as source of bleeding

    Time frame: Through study completion, an average of 1 year

  2. Prevalence of inflammatory lesions as source of bleeding

    Detection of inflammatory lesions as source of bleeding

    Time frame: Through study completion, an average of 1 year

  3. Prevalence of tumor lesions as source of bleeding

    Detection of tumor lesions as source of bleeding

    Time frame: Through study completion, an average of 1 year

  4. Complications of small bowel capsule endoscopy

    Complications of small bowel capsule endoscopy

    Time frame: Through study completion, an average of 1 year

  5. Technical success of small bowel capsule endoscopy

    Technical success is defined as arrival of the capsule in the cecum

    Time frame: Through study completion, an average of 1 year

  6. Time between diagnostic small bowel capsule endoscopy and small bowel enteroscopy for treatment of bleeding

    Time between diagnostic mall bowel capsule endoscopy and small bowel enteroscopy for treatment of bleeding

    Time frame: From time to the end of capsule endoscopy until beginning of small bowel enteroscopy

06

Study locations

1 of 1 sites recruiting
  • University Medical Center Freiburg, Department of Medicine II
    Freiburg im Breisgau, 79106, Germany
    Recruiting
07

References and documents

Publications

  • Rondonotti E, Spada C, Adler S, May A, Despott EJ, Koulaouzidis A, Panter S, Domagk D, Fernandez-Urien I, Rahmi G, Riccioni ME, van Hooft JE, Hassan C, Pennazio M. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review. Endoscopy. 2018 Apr;50(4):423-446. doi: 10.1055/a-0576-0566. Epub 2018 Mar 14. PubMed 29539652 ↗

Individual participant data

Plan to share: No — IPD are shared on reasonable request to the Principal Investigator.

08

Registry details

Key details

Study ID
NCT05949268
Lead sponsor
University Hospital Freiburg
Responsible party
Prof. Dr. Dominik Bettinger (Principal Investigator, University Hospital Freiburg) — Principal investigator
First posted
Jul 18, 2023
Start date
Sep 1, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 15, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Michael Schultheiss, MD
Contact
michael.schultheiss@uniklinik-freiburg.de
+49761/270-34010
Dominik Bettinger, MD
Contact
dominik.bettinger@uniklinik-freiburg.de
+49761/270-36870
Michael Schultheiss, MD
principal investigator · University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion